Invention Grant
- Patent Title: RET kinase inhibitors
-
Application No.: US17519878Application Date: 2021-11-05
-
Publication No.: US11697647B2Publication Date: 2023-07-11
- Inventor: Gabrielle R. Kolakowski , Erin D. Anderson , Steven W. Andrews , Christopher Pierre Albert Jean Boldron , Kevin R. Condroski , Thomas C. Irvin , Manoj Kumar , Elizabeth A. McFaddin , Megan L. McKenney , Johnathan Alexander McLean , Tiphaine Mouret , Michael J. Munchhof , Thomas Pierre Dino Pancaldi , Michael Alexander Pilkington-Miksa , Marta Pinto
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Bradley W Crawford
- Main IPC: C07D413/12
- IPC: C07D413/12 ; A61P35/00 ; C07D231/38 ; C07D401/04 ; C07D401/12 ; C07D403/12 ; C07D413/14 ; C07D417/12 ; C07D417/14
Abstract:
Disclosed herein are compounds of formula I:
or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
Public/Granted literature
- US20220144816A1 RET KINASE INHIBITORS Public/Granted day:2022-05-12
Information query
